Literature DB >> 23384436

Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study.

Yoshinori Takeuchi1, Yasuhito Fujino, Manabu Watanabe, Masashi Takahashi, Takayuki Nakagawa, Ayano Takeuchi, Makoto Bonkobara, Tetsuya Kobayashi, Koichi Ohno, Kazuyuki Uchida, Kazushi Asano, Ryohei Nishimura, Hiroyuki Nakayama, Sumio Sugano, Yasuo Ohashi, Hajime Tsujimoto.   

Abstract

The objective of this retrospective cohort study was to validate the prognostic value of histological grading of canine cutaneous mast cell tumours (MCTs) according to the Patnaik (grades I-III) and Kiupel (low, high) grading systems, and to confirm the prognostic significance of internal tandem duplications (ITDs) within exon 11 of the c-kit gene (ITD-Exon11). The baseline characteristics and outcome data from 47 dogs diagnosed with cutaneous MCTs were collected and reviewed. Tumours were graded according to both grading systems and the nucleotide sequence of c-kit was evaluated. Results were analyzed to evaluate predictive factors for overall survival (OS) and progression-free survival (PFS). Log-rank tests indicated that dogs with Patnaik grade III MCTs had significantly reduced OS and PFS compared to those with either grade I or II tumours. However, no significant difference in OS or PFS was observed between grade I and II tumours. The dogs with Kiupel high-grade MCTs had significantly shorter OS and PFS than dogs with low-grade MCTs. The presence of ITD-Exon11 was significantly associated with shorter PFS. The result of Cox regression analysis showed that the Kiupel grading system for OS and PFS, and lymph node metastasis for OS, independently predicted prognosis. Kappa statistics confirmed a significantly higher inter-observer consistency for the Kiupel compared to the Patnaik grading system. These findings demonstrate that the Kiupel grading system is a useful prognostic tool for canine cutaneous MCTs in predicting OS and PFS, while the occurrence of ITD-Exon11 appeared to be a useful predictor for PFS.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23384436     DOI: 10.1016/j.tvjl.2012.11.018

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  14 in total

1.  Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade.

Authors:  Hiroyuki Mochizuki; Rachael Thomas; Scott Moroff; Matthew Breen
Journal:  Chromosome Res       Date:  2017-01-05       Impact factor: 5.239

2.  Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.

Authors:  Johanna E Todd; Sandra M Nguyen; Joanna White; Veronika Langova; Penelope M Thomas; Sophia Tzannes
Journal:  Can Vet J       Date:  2021-12       Impact factor: 1.008

3.  c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies.

Authors:  Rosa Patruno; Ilaria Marech; Nicola Zizzo; Michele Ammendola; Patrizia Nardulli; Claudia Gadaleta; Marcello Introna; Gennaro Capriuolo; Rosa Angela Rubini; Domenico Ribatti; Cosmo Damiano Gadaleta; Girolamo Ranieri
Journal:  Biomed Res Int       Date:  2014-05-12       Impact factor: 3.411

4.  Evaluation of information presented within mast cell tumour histopathology reports in the United States: 2012-2015.

Authors:  Jennifer K Reagan; Laura E Selmic; Caroline Fallon; Elizabeth A Driskell; Laura D Garrett
Journal:  Vet Med Sci       Date:  2018-06-07

5.  Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs.

Authors:  Jaime A Olsen; Maurine Thomson; Kathleen O'Connell; Ken Wyatt
Journal:  Vet Med Sci       Date:  2018-05-24

6.  The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.

Authors:  Fabio Gentilini; Maria Elena Turba; Claire Dally; Masamine Takanosu; Sena Kurita; Makoto Bonkobara
Journal:  BMC Vet Res       Date:  2020-02-19       Impact factor: 2.741

7.  Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline.

Authors:  L Marconato; E Zorzan; M Giantin; S Di Palma; S Cancedda; M Dacasto
Journal:  J Vet Intern Med       Date:  2013-12-26       Impact factor: 3.333

8.  Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors.

Authors:  Rodrigo Dos Santos Horta; Antonio Giuliano; Gleidice Eunice Lavalle; Mariana de Pádua Costa; Roberto Baracat de Araújo; Fernando Constantino-Casas; Jane Margaret Dobson
Journal:  Oncol Lett       Date:  2017-11-01       Impact factor: 2.967

Review 9.  Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment.

Authors:  Vanessa S Tamlin; Cynthia D K Bottema; Anne E Peaston
Journal:  Vet Med Sci       Date:  2019-10-24

10.  Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors.

Authors:  Eleonora Zorzan; Katia Hanssens; Mery Giantin; Mauro Dacasto; Patrice Dubreuil
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.